↓ Skip to main content

Association between β-blocker use and mortality in critically ill patients: a nested cohort study

Overview of attention for article published in BMC Pharmacology and Toxicology, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#33 of 399)
  • High Attention Score compared to outputs of the same age (85th percentile)

Mentioned by

twitter
19 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Association between β-blocker use and mortality in critically ill patients: a nested cohort study
Published in
BMC Pharmacology and Toxicology, May 2018
DOI 10.1186/s40360-018-0213-6
Pubmed ID
Authors

Shmeylan A. Al Harbi, Khalid A. Al Sulaiman, Hani Tamim, Hasan M. Al-Dorzi, Musharaf Sadat, Yaseen Arabi

Abstract

β-blockers have several indications in critically ill patients and are commonly used. The aim of this study is to examine the relationship between the use of β-blockers in critically ill patients and mortality. This was a nested cohort study in which all medical-surgical ICU patients (N = 523) enrolled in a randomized clinical trial of intensive insulin therapy (ISRCTN07413772) were grouped according to β-blocker use during ICU stay. To account for the indication of β-blockers, we constructed a propensity score using selected clinically-relevant and statistically-significant variables related to β-blocker exposure and outcome. The primary endpoints were all-cause ICU and hospital mortality. Secondary endpoints were the development of severe sepsis during ICU stay, ICU and hospital length of stay, and mechanical ventilation duration. Using multivariable models, we adjusted the associations of β-blockers and these outcomes to the propensity score. Of the 523 patients enrolled in the study, 89 (17.0%) received β-blockers during their ICU stay. There were no significant associations between β-blocker therapy and ICU mortality (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 0.83-2.9, P = 0.16), hospital mortality (aOR 1.09, 95% CI 0.99-1.20, P = 0.73), the risk of ICU-acquired severe sepsis (aOR 1.67, 95% CI 0.95-2.97, P = 0.08), mechanical ventilation duration (P = 0.17), or ICU length of stay (P = 0.22). However, β-blocker use was associated with increased ICU and hospital mortality among nondiabetic patients (aOR 2.93, 95% CI 1.19-7.23, and 2.43, 95% CI 1.05-5.64, respectively). Our study showed that β-blockers during the ICU stay had no significant association with mortality or morbidity. However, β-blocker therapy was associated with increased mortality in non-diabetic patients. ISRCTN07413772 ; (dated 13.07.2005).

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 18%
Student > Ph. D. Student 3 11%
Other 2 7%
Student > Bachelor 2 7%
Student > Master 2 7%
Other 1 4%
Unknown 13 46%
Readers by discipline Count As %
Medicine and Dentistry 8 29%
Biochemistry, Genetics and Molecular Biology 2 7%
Social Sciences 2 7%
Nursing and Health Professions 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Other 1 4%
Unknown 13 46%

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 August 2021.
All research outputs
#1,892,573
of 20,856,737 outputs
Outputs from BMC Pharmacology and Toxicology
#33
of 399 outputs
Outputs of similar age
#42,885
of 296,610 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#1
of 1 outputs
Altmetric has tracked 20,856,737 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 399 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,610 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them